Effects of tacrolimus and cyclosporine A on inflammatory cytokines and blood lipid after renal transplantation

Journal of Clinical Rehabilitative Tissue Engineering Research

Volumn 15, Issue 31, 2011, Pages 5769-5772

  Ke Pu, Liu ^a   Xiao Min, Yi ^a   Shuai Jun, Ma ^a   Zhi Bin, Li ^a   Geng, Zhang ^a   Jian Lin, Yuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOKINE; GLUCOCORTICOID; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

EID: 80051661819     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-8225.2011.31.016     Document Type: Article

References (20)

1. Arce J, Rosales A, Caffaratti J, et al. Renal retransplantation: risk factors and results. Actas Urol Esp. 2011;35(1):44-50.
2. Steinmetz OM, Stahl RA, Panzer U. Chemokines and B cells in renal inflammation and allograft rejection. Front Biosci. 2009;1:13-22.
3. Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: diagnosis and treatment. Curr Diab Rep. 2009;9(4):305-311.
4. Calmus Y, Pageaux G. Renal failure following liver transplantation. Presse Med. 2009;38(9):1314-1318.
5. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227-2243.
6. Knoll G. Trends in kidney transplantation over the past decade. Drugs. 2008;68(Suppl 1):3-10.
7. Vicari-Christensen M, Repper S, Basile S, et al. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant. 2009;19(3):277-284.
8. Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant. 2010;10(5):1126-1134.
9. Wang YL. Touxi yu Rengong qiguan. 2008;19(1):35-38.
10. Tang CH, Liu W, Ling JY. Shanghai Jiaotong Daxue Xuebao. 2006;26(6):685-688.
11. Fischereder M, Schroppel B. The role of chemokines in acute renal allograft rejection and chronic allograft injury. Front Biosci. 2009;14:1807-1814.
12. Montague T, Murphy B. Lipid management in chronic kidney disease, hemodialysis, and transplantation. Endocrinol Metab Clin North Am. 2009;38(1):223-234.
13. Mimori T. Immunosuppressants. Nippon Rinsho. 2009;67(3):582-587.
14. Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics. 2008;9(5):585-596.
15. Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007;33(3):211-220.
16. Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging. 2009;26(9):715-737.
17. Cantarovich D, Vistoli F, Soulillou JP. Immunosuppression minimization in kidney transplantation. Front Biosci. 2008;13:1413-1432.
18. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008;9(4):635-643.
19. Sánchez-Pérez J. Safety information for tacrolimus: present and future. Actas Dermosifiliogr. 2008;99(Suppl 2):19-25.
20. Guo J, Qu QS, Zhu MH, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010;14(44):8207-8210.